KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Free Cash Flow (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Free Cash Flow for 13 consecutive years, with -$4.7 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 55.0% to -$4.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$39.6 million through Dec 2025, up 39.05% year-over-year, with the annual reading at -$39.6 million for FY2025, 39.05% up from the prior year.
  • Free Cash Flow hit -$4.7 million in Q4 2025 for Arbutus Biopharma, up from -$5.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $20.5 million in Q1 2022 to a low of -$27.4 million in Q1 2023.
  • Historically, Free Cash Flow has averaged -$14.8 million across 5 years, with a median of -$17.2 million in 2022.
  • Biggest five-year swings in Free Cash Flow: surged 214.26% in 2022 and later crashed 233.46% in 2023.
  • Year by year, Free Cash Flow stood at -$19.7 million in 2021, then rose by 12.92% to -$17.1 million in 2022, then dropped by 0.98% to -$17.3 million in 2023, then soared by 39.85% to -$10.4 million in 2024, then surged by 55.0% to -$4.7 million in 2025.
  • Business Quant data shows Free Cash Flow for ABUS at -$4.7 million in Q4 2025, -$5.8 million in Q3 2025, and -$15.7 million in Q2 2025.